今天有朋友问我，未来5-10年，股市我是看好白酒产业，还是看好生物医药？

Group 1 - The company believes that the liquor industry will perform better than the biopharmaceutical industry over the next 5-10 years due to its status as a mass consumer product essential for social and business activities [2][3] - The liquor market is expected to remain a significant part of social consumption as long as the economy does not face major downturns, indicating a stable demand for liquor [2] - In contrast, the biopharmaceutical industry is perceived as having limited growth potential in China due to government intervention leading to high prices and monopolistic conditions, which restricts the market size and profitability [2][3] Group 2 - The company anticipates that as living standards improve, consumers will likely spend more on liquor rather than on pharmaceuticals, suggesting a preference for social consumption over medical expenses [3] - The expectation is that spending on biopharmaceuticals will not increase significantly, as improvements in living standards do not correlate with higher medication consumption [3]